ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
| Metabolism | Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI). |
| Excretion | Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%). |
| Half-life | Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours. |
| Protein binding | Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein). |
| Volume of Distribution | Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution). |
| Bioavailability | Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%. |
| Onset of Action | Oral: acetaminophen 30-60 min, pentazocine 15-30 min. Intramuscular: pentazocine 15-20 min. Intravenous: pentazocine 2-3 min. |
| Duration of Action | Oral: acetaminophen 4-6 hours, pentazocine 3-4 hours. Intramuscular/Intravenous: pentazocine 2-3 hours. |
| Molecular Weight | 531.6 Da (acetaminophen 151.2, pentazocine HCl 380.4) |
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
| Dosage form | TABLET |
| Renal impairment | CrCl 30-50 mL/min: use with caution; decrease dose interval to every 6 hours if needed. CrCl <30 mL/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation. |
| Pediatric use | Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg). |
| Geriatric use | Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen. |
| 1st trimester | Pentazocine and acetaminophen both cross the placenta. Use only if clearly needed. Animal studies have shown evidence of teratogenicity with pentazocine at high doses, but controlled human data are limited. |
| 2nd trimester | No significant teratogenic risk identified from acetaminophen; pentazocine use may lead to neonatal withdrawal. Use only if potential benefit outweighs risk. |
| 3rd trimester | Chronic use may cause neonatal opioid withdrawal syndrome. Acetaminophen generally safe but pentazocine may cause respiratory depression in newborn if used near term. |
Clinical note
CNS depressants may enhance sedative effects Can cause withdrawal in patients dependent on other opioids.
| Placental transfer | Both drugs cross the placenta. Acetaminophen crosses readily; pentazocine crosses sufficiently to produce fetal blood levels. |
| Breastfeeding | Both drugs are excreted into breast milk in low amounts. Acetaminophen is considered compatible. Pentazocine levels are low but may cause sedation in the infant. No adverse effects reported with occasional use. Caution with prolonged use. |
■ FDA Black Box Warning
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
| Common Effects | Dizziness |
| Serious Effects |
Hypersensitivity to acetaminophen or pentazocineAcute or severe asthma (potential respiratory depression)Opioid addiction or dependence (due to pentazocine)Severe hepatic impairment (acetaminophen toxicity)MAO inhibitors within 14 days (serious drug interaction)
| Precautions | Respiratory depression risk, especially in patients with compromised respiratory function, Potential for opioid dependence, abuse, and misuse, Risk of withdrawal if discontinued abruptly after prolonged use, Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists, Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease, Central nervous system depression additive with other CNS depressants, Elderly or debilitated patients may have increased sensitivity to effects, May cause hypotension, especially in hypovolemic patients, Serotonin syndrome risk when used with serotonergic drugs, Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects |
Loading safety data…
| Lactation Rating | L2 (Possibly compatible) |
| Teratogenic Risk | Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term. |
| Fetal Monitoring | Maternal: Liver function tests (hepatotoxicity risk with high-dose acetaminophen), renal function, CNS depression, respiratory rate (pentazocine). Fetal: Ultrasound for growth and well-being if chronic use; neonatal monitoring for withdrawal symptoms and respiratory depression after delivery near term. |
| Fertility Effects | Acetaminophen: No known negative impact on fertility. Pentazocine: Chronic use may disrupt reproductive function due to opioid effects on hormonal axes (e.g., decreased libido, amenorrhea); data are limited. Reversible upon discontinuation. |
| Food/Dietary | Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs. |
| Clinical Pearls | Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential. |
| Patient Advice | Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications). · Avoid alcohol while taking this medication; risk of liver damage increases. · This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known. · Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine). · Do not suddenly stop if used long-term; withdrawal symptoms may occur. · If you have opioid dependence, this medication may precipitate withdrawal symptoms. · This medication may cause constipation; maintain fluid and fiber intake. |